Abstract
Neuroanatomical connections point to possible interactions between areas influencing energy homeostasis and those influencing cognition. We assessed whether serum leptin, thyroxine and thyroid stimulating hormone (TSH) levels are associated with and interact to influence cognitive performance among US adults. Data from the National Health and Nutrition Examination Survey III (1988–94) were used. Measures included a battery of neuropsychological tests and serum leptin, thyroxine and TSH levels (20–59yo: n=1114–2665; 60–90yo: n=1365–5519). Among those 20–59yo, the middle tertile of leptin (vs. first tertile) was inversely related to the number of errors on the symbol digits substitution test. Increased thyroxine level was associated with a poorer performance on the serial digits test in 20–59yo, but a better performance on the Math test in 60–90yo. TSH was associated with poor performance on various tests in 20–59yo, but better performance in 60–90yo. Significant antagonistic interactions were found in both age groups between thyroxine, TSH and leptin for a number of tests, including between leptin and thyroxine in 60–90yo in their association with word recall-correct score. We found significant associations of our main exposures with cognitive function among US adults, going in opposite directions between age groups in the cases of thyroid hormonal levels, as well as some interactive effects between exposures. It is important to conduct prospective cohort studies to provide further insight into potential interventions that would assess interactive effects of various hormonal replacement regimens.
Keywords: Leptin, thyroxine, thyroid stimulating hormone, cognitive function, aging
INTRODUCTION
Thyroid hormones and the adipokine hormone leptin are both determinants of adiposity, through the regulation of energy metabolism, thermogenesis, glucose and lipid metabolism, appetite and food intake, and the oxidation of fatty acids (Biondi, 2010, Farooqi, et al., 2007, Jacob, et al., 1997, Zhang, et al., 1994). Findings from a recent meta-analysis (Beydoun, et al., 2008) linked poor cognitive function, and increased Alzheimer’s Disease risk, by approximately 80% to obesity (i.e. higher adiposity status as measured by body mass index ≥30 kg.m−2). Hormonal mechanisms underlying the association between obesity and poor cognition are still understudied. Interestingly, thyroid hormones are also key actors on the central nervous system during neuro-development (Anderson, 2001, Dugbartey, 1998), by regulating nervous system myelination, growth, puberty, metabolism and organ functions (Smith, et al., 2002). In adults (Hendrick, et al., 1998, Loosen, 1992), the brain becomes more sensitive to thyroid function changes, a rationale behind using thyroid hormones to treat psychiatric and affective disorders (Bauer and Whybrow, 2001). Additionally, hypothyroidism was linked to progressive cognitive impairment and slower thought processes, leading to pseudo-dementia, a condition used to rule out primary degenerative dementia (Dugbartey, 1998, Loosen, 1992). However, despite the well-established effects of hypothyroidism on cognitive function, the effects of hormonal levels within normal ranges are less well-studied. Research suggests that thyroxine (T4) and thyroid stimulating hormone (TSH) fluctuations within normal or pre-clinical ranges may be associated with cognitive performance. Evidence suggests hypothyroidism as a potential risk factor for cognitive impairment in some studies (Bono, et al., 2004, Burmeister, et al., 2001, Correia, et al., 2009, Mafrica and Fodale, 2008, Miller, et al., 2006, Monzani, et al., 1993, Osterweil, et al., 1992, Prinz, et al., 1999, Samuels, et al., 2007a, Volpato, et al., 2002, Wahlin, et al., 1998) but not others (Almeida, et al., 2007, Kramer, et al., 2009, Samuels, et al., 2007b).
New evidence suggests that the adipokine hormone leptin, originally linked to appetite and eating behavior by acting on the hypothalamus and striatal brain regions (Farooqi, et al., 2007, Jacob, et al., 1997, Zhang, et al., 1994), has pleiotropic effects within the cortex and hippocampus involved in cognition. In fact, when leptin was administered directly into the hippocampus of mice, it was shown to improve memory processing and to shape the hypothalamus during the earliest stages (Harvey, et al., 2005). A number of recent epidemiological studies indicate an association (Gunstad, et al., 2008, Holden, et al., 2009, Paz-Filho, et al., 2008), yet it remains unclear whether there are interactions between areas influencing energy homeostasis and cognition, despite well-established neuroanatomical connections suggesting this (Morrison, 2009). As both thyroid hormones and leptin may be involved in cognition by potentially mediating the effect of adiposity on brain function, it is important to assess whether their effects are interactive or simply additive. The present study used cross-sectional nationally representative data from the National Health and Nutrition Examination Survey (NHANES) III to examine associations and interactions of leptin, T4 and TSH levels with various tests of cognitive performance among adults in the United States.
METHODS
Participants
NHANES III (1988–1994), a multistage, stratified sampling design, over-sampled older adults (60–90yo) and minorities (African Americans and Mexican Americans). Following a home-interview, selected individuals were invited to a mobile examination center (MEC) for body measurements, clinical evaluations and laboratory testing (Center for Disease Control and Prevention (CDC), 1996). Among adults (aged 20–90yo) interviewed, 12,264 were 20–59yo and 6,033 were 60–90yo. Two separate and distinctive batteries of cognitive function tests were administered to those two age groups, respectively. Cognitive testing was available on a smaller proportion (n=3288 of 12,264) of 20–59yo compared to 60–90yo (n=5811 to 6033 out of 6,033). Among participants with complete cognitive, demographic, lifestyle and health-related data, thyroxine and TSH data were generally complete in both age groups (2,496 to 2,665: 20–59yo and 4,086 to 5,519: 60–90yo). However, a small proportion of those with complete cognitive data also had leptin data (1,114 to 1,164: 20–59yo; 1,365 to 1,420:60–90yo) (See Figure 1).
Figure 1. Study sample selection.
Abbreviations: NHANES=National Health and Nutrition Examination Surveys; TSH=Thyroid Stimulating Hormone.
Cognitive assessment
As part of the MEC exam, a battery of three cognitive tests was administered to participants aged 20–59yo and considered in our present study: simple reaction time (SRT), symbol-digit substitution test (SDS) and serial digits learning (SDL), from which five cognitive test scores were computed. Among those aged 60–90yo, three cognitive tests were administered and used in our present study: Word recall (WR), story recall (SR), a math test (also termed serial 3’ s; MATH) and orientation to time from the mini-mental state examination (ORIENT), (Folstein, 1975) (See Online Supplemental Material).
Laboratory assessments
Serum leptin
After an overnight fast, surplus sera from 6,415 participants (20–90yo) was tested for leptin level (in Fg/L) by the laboratory Linco Research, Inc., St. Louis, Missouri, using a radioimmunoassay (RIA) with a polyclonal antibody raised in rabbits against highly purified recombinant human leptin. The minimum detectable concentration of the assay was 0.5 Fg/L leptin and the limit of linearity was 100 Fg/L. Recovery of leptin added to serum is 99–104% over the linear range of the assay. The RIA agrees reasonably well with rough quantification by Western blot. Within-and between-assay CVs range from 3.4% to 8.3% and from 3.6% to 6.2%, respectively. (US DHHS, 2002)
Serum total circulating thyroxine (T4)
Thyroxine (in μg/dL; 1 nmol/L=12.8 μg/dL) testing was performed on examinees aged 13–90yo. Total (protein-bound and free) circulating thyroxine (T4) concentrations were determined using an enzyme-based homogeneous immunoassay on the Hitachi 704. The reference range is 4.5 to 12.5 μg/dL. The coefficient for inter-assay variation (CV) was less than 10%. (Gunter, 2010)
Serum thyroid stimulating hormone
The thyroid stimulating hormone (TSH, in mu/L) assay is a chemiluminescence immunometric assay utilizing a mouse monoclonal antibody to TSH immobilized on a polystyrene bead and a goat polyclonal antibody to TSH conjugated with an acridinium ester. The reference range is 0.3 to 5.0 mu/L. The coefficient for inter-assay variation (CV) was less than 5%. (Gunter, 2010)
Covariates
In multiple age group-specific (20–59yo; 60–90yo) regression models, covariates considered as potential confounders included age (continuous), sex, race/ethnicity (Non-Hispanic White (NHW), Non-Hispanic black (NHB), Mexican-American (MA), Other ethnicity (OTHER)), marital status (0=unmarried; 1=currently married), educational level (<High school, High school, >High school), poverty income ratio (≤100%; >100-≤200%; >200%), language of interview (1=English; 2=Spanish) and smoking status coded as: “Never”, “Former” and “Current”. Moreover, self-reported physical activity compared to age peers was selected, with possible responses: “More active”; “About the same” and “less active”. Weight status was measured using the body mass index (weight(kg) divided by squared height (m−2)).
To assess overall dietary quality, a widely-used and readily available diet quality index, the USDA’s 1995-Health Eating Index (HEI) (McCullough, et al., 2000) (range: 0–100) was employed, with higher scores reflecting better dietary quality. Quintiles score were computed and entered into models as four dummy variables (common referent: lowest quintile).
Participants self-rated their health as follows: Would you say your health in general is “Excellent”, “Very good”, “Good”, “Fair” or “Poor”? The variable was entered into models as four dummy variables (common referent: “Excellent”). Finally, an index was created using self-reported co-morbid conditions namely “arthritis“, “congestive heart failure“, “stroke“, “asthma“, “chronic bronchitis“, “emphysema“, “hay fever“, “cataracts“, “goiter“, “thyroid disease“, “lupus“, “gout“, “skin cancer”, “other cancer”, “diabetes”, “hypertension”, “chest pain/possible angina”, “heart attack/myocardial infarction”, “osteoporosis” and “kidney stones“. Thus, a participant’s value on this index may range between 0 and 20.
Data analysis
Stata release 11.0 (STATA, 2009) was used for analyzing survey data. Two design variables were specified for the six-year period of NHANES III, namely the primary sampling unit and the stratum. Sampling weights used were those for cognitive testing variables (six-year) in the case of 20–59yo sub-group and those for the MEC exam (six-year) for those aged 60–90yo. Means, proportions and regression coefficients were estimated taking into account design complexity and sampling weights. Main exposures were Loge transformed and categorized as tertiles in the major part of the analysis, which consisted of the following steps: First, means of Loge transformed leptin, thyroxine and TSH were graphically represented using dot plots, comparing age group-sex categories in one analysis and age group-race in another. To statistically test differences between categories in each analysis and for each exposure variable, ANOVA test was conducted taking sampling weights into account, followed by bonferroni-corrected multiple comparisons. Second, sample characteristics were described, compared between the two age groups (by assessing 95% CI overlap) and then entered into a multiple OLS regression model as predictors for the three main exposure variables (Loge transformed). Third, for each age subgroup, multiple OLS and zero-inflated poisson regression models were conducted with cognitive function scores as outcomes and the three main exposure variables (Loge transformed and converted to tertiles) entered separately in each model along with potentially confounding socio-demographic, lifestyle and health-related factors.
OLS models were conducted for continuous pseudo-normal cognitive scores (usually involving time elapsed to complete the test; 20–59yo), whereas zero-inflated poisson regression models were conducted in the tests for 60–90yo which were count outcomes with a large proportion scoring as zero (e.g. no errors on the test=zero score). Finally, pairwise interaction between the three main exposures was tested in OLS and the zero-inflated poisson models. Additionally, three secondary analyses were conducted: First, effect modification by sex and race of the associations between the three exposures and the various cognitive outcomes was tested by adding interaction terms alternatively with sex and race to the main effects model. Second, analyses were repeated for the total sample after excluding participants with extreme values on thyroxine and TSH (i.e. outside the reference range). A type I error of 0.05 was considered for statistical significance in all analyses, except for interaction terms where significance level was set at 0.10 (Selvin, 2004).
RESULTS
Study sample characteristics
Table 1 displays estimated means and proportions of main study characteristics. Generally, the younger age group (20–59yo) had a higher proportion of participants using Spanish as the interview language (5.2% vs. 1.4%), more current smokers (33.5% vs.18.7), excellent self-rated health (23.4% vs. 10.2%) and were more active than age peers (22.0% vs. 13.5%). However, the older age group (60–90yo) had an overall healthier diet (1995-HEI: 65.7 vs. 61.8), but a higher mean co-morbidity index (2.6 vs. 1.07). Leptin, thyroxine and TSH levels were significantly elevated in the 60–90yo group.
TABLE 1.
Study sample characteristics by age group; NHANES III
| 20–59y | 60–90y | |||||
|---|---|---|---|---|---|---|
| N | Mean or % | SE | N | Mean or % | SE | |
| Age | 3241 | 36.7 | 0.3 | 6033 | 72.5 | 1.6 |
| Female, % | 3241 | 51.5 | 1.1 | 6033 | 45.2 | 7.7 |
| Race/ethnicity, % | 3241 | 6033 | ||||
| NH White | 75.0 | 2.7 | 82.6 | 6.0 | ||
| NH Black | 12.0 | 1.5 | 13.0 | 5.9 | ||
| Mexican-American | 5.8 | 1.2 | 1.7 | 0.4 | ||
| Other ethnicity | 7.2 | 1.6 | 2.7 | 7.3 | ||
| Married, % | 3241 | 60.4 | 2.1 | 6033 | 67.4 | 5.4 |
| Education, % | 3241 | 6009 | ||||
| <High School | 7.6 | 1.0 | 26.7 | 6.1 | ||
| High School | 48.2 | 2.0 | 36.6 | 6.5 | ||
| >High School | 44.2 | 2.4 | 36.7 | 10.0 | ||
| Poverty income ratio, % | 3241 | 6033 | ||||
| 0–100% | 11.7 | 1.1 | 8.4 | 1.5 | ||
| >100%–200% | 18.3 | 1.7 | 26.3 | 6.1 | ||
| >200% | 70.0 | 2.1 | 65.3 | 6.5 | ||
| Language of interview | 3241 | 6014 | ||||
| English | 94.8 | 1.2 | 98.6 | 0.3 | ||
| Spanish | 5.2 | 1.2 | 1.4 | 0.3 | ||
| Cigarette smoking status | 3241 | 6033 | ||||
| Never | 45.7 | 1.6 | 35.0 | 6.0 | ||
| Former | 20.8 | 1.1 | 46.3 | 8.7 | ||
| Current | 33.5 | 1.7 | 18.7 | 5.8 | ||
| Self-rated health | 3241 | 6033 | ||||
| Excellent | 23.4 | 1.4 | 10.2 | 2.1 | ||
| Very good | 31.6 | 1.6 | 33.2 | 10.4 | ||
| Good | 32.2 | 1.3 | 33.5 | 6.9 | ||
| Fair | 11.0 | 1.1 | 16.5 | 2.9 | ||
| Poor | 1.9 | 0.4 | 6.3 | 1.2 | ||
| 1995-Healthy Eating Index, % | 3177 | 5875 | ||||
| Mean | 61.8 | 0.5 | 65.7 | 1.6 | ||
| Q1: poor quality diet | 6.4 | 0.6 | 6033 | 9.6 | 5.9 | |
| Q5: better quality diet | 16.1 | 1.2 | 28.0 | 4.9 | ||
| Physical activity | 3183 | 5921 | ||||
| More active | 22.0 | 1.4 | 13.5 | 2.4 | ||
| About the same | 47.0 | 1.6 | 38.8 | 7.1 | ||
| Less active | 31.0 | 1.4 | 47.7 | 8.5 | ||
| Co-morbidity index, Mean | 3205 | 1.07 | 0.03 | 6025 | 2.6 | 0.1 |
| Body mass index, kg.m−2, Mean | 3231 | 26.2 | 0.2 | 6012 | 26.6 | 0.1 |
| Leptin level, Loge-transformed | 1293 | 1.94 | 0.06 | 1673 | 2.25 | 0.03 |
| T1 | R: −0.69;1.79 | M:1.13 | R:−0.22;1.79 | M:1.33 | ||
| T2 | R:1.81;2.83 | M:2.32 | R:1.81;2.83 | M:2.32 | ||
| T3 | R:2.83;4.33 | M:3.19 | R:2.83;4.55 | M:3.20 | ||
| Thyroxine level, Loge-transformed | 3241 | 2.67 | 0.06 | 6033 | 2.93 | 0.19 |
| T1 | R: −0.92; 2.06 | M:1.94 | R:−0.92;2.07 | M:2.00 | ||
| T2 | R: 2.08;2.20 | M:2.14 | R:2.08;2.20 | M:2.19 | ||
| T3 | R:2.21;3.40 | M:2.32 | R:2.21;2.92 | M:2.31 | ||
| Thyroid stimulating hormone, Loge-transformed | 2976 | 0.32 | 0.02 | 5671 | 0.47 | 0.13 |
| T1 | R:−4.60;0.18 | M:−0.13 | R:−4.60;0.18 | M:−0.25 | ||
| T2 | R:0.22;0.77 | M:0.47 | R:0.22;0.77 | M:0.47 | ||
| T3 | R:0.79;5.50 | M:1.03 | R:0.79;4.76 | M:1.03 | ||
| Cognitive performance scores | ||||||
| SRT | 2928 | 233.4 | 1.5 | — | — | — |
| SDS-L | 2895 | 22.8 | 0.3 | — | — | — |
| SDS-E | 2895 | 1.4 | 0.1 | — | — | — |
| SDL-TTC | 2807 | 4.5 | 0.2 | — | — | — |
| SDL-TE | 2739 | 4.6 | 0.1 | — | — | — |
| WR-CORR | — | —— | 4674 | 5.42 | 0.07 | |
| WR-TRIALS | — | —— | 5754 | 0.04 | 0.01 | |
| SR-CORR | — | —— | 5878 | 3.38 | 0.54 | |
| MATH-INC | — | —— | 5989 | 1.51 | 0.46 | |
| ORIENT-INC | — | —— | 5615 | 1.88 | 0.02 | |
Abbreviations: M=Median; MATH-INC=Math test-Incorrect; NH=Non-Hispanic; NHANES=National Health and Nutrition Examination Surveys; OLS=Ordinary Least Square; ORIENT-INC=Orientation to time, incorrect items; SDS-L=Symbol Digits Substitution tests-Latencies; SDS-E=Symbol Digits Substitution tests-Errors; Serial Digits Learning-Trials to criterion; SDL-TE=Serial Digits Learning-Total Errors; SE=Standard error; SR-CORR=Story recall-correct; SRT=Simple reaction time; T=tertile; WR-CORR=Word Recall-Correct; WR-TRIALS=Word Recall-Number of Trials.
Associations of leptin, thyroxine and thyroid stimulating hormone with socio-demographic, lifestyle and health-related factors
Based on Figure 2 which examined and compared weighted means of each Loge transformed exposure across age group-sex categories, the following patterns were observed within age group and across sex: First, leptin and T4 levels were significantly more elevated among women compared to men in both age groups, while TSH level was significantly higher among women in the 60–90yo group but lower among women in the 20–59yo age group, compared to men in that age group. Figure 3 shows significant race differences in levels of Loge transformed exposures within each age group. For instance, leptin level was significantly lower among NHW particularly within the 20–59yo age group (compared to NHB and MA). T4 level on the other hand did not differ significantly within the 60–90yo age group and across race, while in the 20–59yo group, NHW had significantly lower levels compared to MA and OTH 20–59yo. TSH level was significantly lower within the 20–59yo group among NHB compared to NHW and the other two race groups. In contrast, in the 60–90yo group, NHB had the highest TSH level compared to the other three race groups.
Figure 2. Dot plot of Loge transformed leptin, thyroxine and TSH by age group and sex; NHANES III.
Abbreviations: ANOVA=Analysis of variance; NHANES=National Health and Nutrition Examination Surveys; T4=Thyroxine; TSH=Thyroid Stimulating Hormone.
*p<0.0001 for ANOVA test comparing mean Loge transformed leptin, T4 and TSH across age-sex groups. All bonferroni-corrected multiple comparisons were statistically significant (p<0.001), except for Loge(leptin) comparing men 20–59yo to men 60–90yo and Loge(TSH) comparing 20–59yo men to 60–90yo women.
Figure 3. Dot plot of Loge transformed leptin, thyroxine and TSH by age group and race; NHANES III.
Abbreviations: ANOVA=Analysis of variance; MA=Mexican-American; NHANES=National Health and Nutrition Examination Surveys; NHB=Non-Hispanic Black; NHW=Non-Hispanic White; OTH=Other ethnicity; T4=Thyroxine; TSH=Thyroid Stimulating Hormone.
*p<0.0001 for ANOVA test comparing mean Loge transformed leptin, T4 and TSH across age-race groups. All bonferroni-corrected multiple comparisons were statistically significant (p<0.05), except for the following:
Loge(leptin): comparing NHW 20–59yo to OTH 20–59yo; comparing NHB 20–59yo to MA 60–90yo; comparing NHW 60–90yo to MA 60–90yo; comparing OTH 60–90yo to NHB 20–59yo, OTH 20–59yo, NHW 60–90yo and NHB 60–90yo; comparing OTH 60–90yo to MA 60–90yo.
Loge(T4): comparing NHW 20–59yo to NHB 20–59yo, NHW 60–90yo and OTH 60–90yo; comparing OTH 20–59yo to 60–90yo(NHB, MA, OTH); comparing NHW 60–90yo to NHB, MA and OTH 60–90yo; comparing NHB 60–90yo to MA and OTH 60–90yo; comparing MA 60–90yo to OTH 60–90yo.
Loge(TSH): comparing NHW 20–59yo to MA 60–90yo; comparing OTH 60–90yo to NHW 20–59yo, NHW 60–90yo, MA 20–59yo, and OTH 20–59yo; comparing MA 60–90yo to OTH 60–90yo.
Based on findings from OLS regression analyses (Table 2), leptin was significantly higher in women in both age groups. It was positively associated with age in the 20–59yo group, but inversely related to age in the 60–90yo group. In the 20–59yo group, leptin was significantly higher among NHB and MA (compared to NHW) and lower among current cigarette smokers (compared to never smokers). It showed an increasing trend with poorer self-rated health, and a decreasing trend with lower physical activity and higher co-morbidity index (20–59yo group) and more importantly a positive association with BMI in both age groups. Thyroxine (20–59yo group) was significantly higher among NHB and lower in OTHER compared to NHW. In the 60–90yo group, thyroxine was positively associated with the 1995-HEI and inversely related to BMI. TSH, on the other hand, was positively associated with age and inversely related to smoking status in the 20–59yo group and it was inversely related to educational attainment and BMI in the 60–90yo group.
TABLE 2.
Multiple OLS regression analysis for predictors of serum leptin, thyroxine and thyroid stimulating hormone, by age group; NHANES III
| 20–59y | 60–90y | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Loge (Leptin) | Loge (Thyroxine) | Loge (TSH) | Loge (Leptin) | Loge (Thyroxine) | Loge (TSH) | |||||||
| β | SEE | β | SEE | β | SEE | β | SEE | β | SEE | β | SEE | |
| N=1265 | N=3141 | N=2889 | N=1628 | N=5856 | N=5523 | |||||||
| Age | 0.010 | 0.003* | −0.005 | 0.004 | 0.009 | 0.002* | −0.004 | 0.003 | −0.000 | 0.010 | −0.004 | 0.003 |
| Female | 1.126 | 0.050* | −0.047 | 0.108 | −0.067 | 0.039 | 0.871 | 0.045* | 0.075 | 0.127 | 0.098 | 0.063 |
| Race/ethnicity (Ref=NH White) | ||||||||||||
| NH Black | 0.009 | 0.045 | 0.428 | 0.125* | −0.231 | 0.040* | 0.007 | 0.060 | 0.215 | 0.182 | −0.108 | 0.073 |
| Mexican-American | 0.084 | 0.071 | 0.167 | 0.136 | −0.036 | 0.054 | −0.002 | 0.114 | 0.613 | 0.586 | −0.150 | 0.107 |
| Other ethnicity | 0.118 | 0.117 | −0.327 | 0.129* | −0.078 | 0.091 | 0.209 | 0.174 | −0.672 | 0.384 | −0.052 | 0.137 |
| Married (Ref=unmarried) | 0.055 | 0.055 | 0.059 | 0.094 | −0.046 | 0.034 | 0.116 | 0.057* | 0.004 | 0.153 | 0.111 | 0.062 |
| Education (Ref≤High School) | ||||||||||||
| High School | −0.037 | 0.093 | −0.006 | 0.207 | 0.111 | 0.071 | 0.091 | 0.080 | 0.179 | 0.181 | −0.063 | 0.057 |
| >High School | 0.052 | 0.109 | 0.033 | 0.180 | 0.051 | 0.082 | 0.017 | 0.087 | 0.152 | 0.206 | −0.206 | 0.074* |
| Poverty income ratio (Ref=0–100%) | ||||||||||||
| >100%–200% | −0.035 | 0.047 | −0.290 | 0.183 | −0.044 | 0.059 | −0.060 | 0.078 | −0.115 | 0.275 | 0.126 | 0.100 |
| >200% | −0.014 | 0.048 | −0.280 | 0.206 | −0.026 | 0.052 | 0.000 | 0.083 | 0.152 | 0.206 | 0.078 | 0.102 |
| Language of interview (Ref=English) | ||||||||||||
| Spanish | −0.069 | 0.100 | 0.066 | 0.155 | 0.125 | 0.088 | −0.115 | 0.167 | 0.018 | 0.282 | 0.122 | 0.155 |
| Cigarette smoking status (Ref=Never) | ||||||||||||
| Former | 0.023 | 0.057 | 0.077 | 0.130 | −0.013 | 0.052 | 0.085 | 0.064 | −0.139 | 0.147 | −0.102 | 0.062 |
| Current | −0.076 | 0.053 | 0.006 | 0.110 | −0.189 | 0.051* | −0.052 | 0.080 | −0.290 | 0.238 | −0.046 | 0.089 |
| Missing | — | −0.429 | 0.228 | −0.716 | 0.118* | — | — | — | ||||
| Self-rated health (Ref=Excellent) | ||||||||||||
| Very good | 0.089 | 0.056 | 0.090 | 0.122 | 0.028 | 0.046 | 0.152 | 0.054* | −0.365 | 0.157* | −0.176 | 0.073* |
| Good | 0.079 | 0.072 | 0.140 | 0.111 | −0.065 | 0.055 | 0.132 | 0.072 | 0.013 | 0.193 | −0.026 | 0.065 |
| Fair | 0.034 | 0.064 | 0.121 | 0.165 | 0.071 | 0.087 | 0.159 | 0.070* | 0.002 | 0.180 | −0.167 | 0.093 |
| Poor | 0.143 | 0.112 | 0.416 | 0.440 | 0.021 | 0.104 | 0.096 | 0.148 | 0.586 | 0.247 | 0.016 | 0.116 |
| Missing | — | — | — | −0.370 | 0.094* | 1.485 | 1.747 | 0.376 | 0.291 | |||
| 1995-Healthy Eating Index (Ref=Q1) | ||||||||||||
| Q2 | 0.158 | 0.123 | −0.204 | 0.202 | 0.042 | 0.062 | −0.019 | 0.124 | 0.920 | 0.273* | −0.156 | 0.100 |
| Q3 | 0.096 | 0.123 | 0.049 | 0.203 | −0.064 | 0.047 | −0.132 | 0.100 | 0.544 | 0.235* | −0.400 | 0.120* |
| Q4 | 0.059 | 0.120 | 0.034 | 0.186 | −0.067 | 0.070 | −0.108 | 0.102 | 0.807 | 0.244* | −0.163 | 0.094 |
| Q5: better quality diet | 0.089 | 0.126 | −0.043 | 0.217 | −0.047 | 0.063 | −0.056 | 0.101 | 0.920 | 0.255* | −0.109 | 0.095 |
| Missing | 0.130 | 0.200 | −0.007 | 0.278 | 0.112 | 0.114 | −0.285 | 0.136* | 0.928 | 0.366* | −0.309 | 0.208 |
| Physical activity (Ref=More active) | ||||||||||||
| About the same | −0.190 | 0.060* | −0.111 | 0.108 | 0.001 | 0.052 | 0.059 | 0.075 | −0.218 | 0.194 | 0.043 | 0.079 |
| Less active | −0.316 | 0.066* | −0.095 | 0.120 | −0.002 | 0.052 | −0.004 | 0.080 | −0.446 | 0.252 | −0.143 | 0.078 |
| Body mass index, kg.m−2 | 0.099 | 0.005* | −0.006 | 0.008 | 0.006 | 0.004 | 0.090 | 0.006* | −0.034 | 0.015* | 0.015 | 0.006* |
| Co-morbidity index | −0.035 | 0.015* | 0.110 | 0.055 | −0.032 | 0.026 | 0.017 | 0.013 | −0.019 | 0.040 | 0.005 | 0.015 |
P<0.05 for null hypothesis that β=0.
Abbreviations: NH=Non-Hispanic; NHANES=National Health and Nutrition Examination Surveys; OLS=Ordinary Least Square; SE=Standard error; Q=Quintile.
The prevalence of hyperthyroidism (i.e. reference range exceeded values) in 20–59yo was 4% for thyroxine and 2.5% for TSH. In 60–90yo prevalence rates were 3% and 7%, respectively. In terms of hypothyroidism (i.e. below the reference range), prevalence was 1.7% for thyroxine and 2.1% for TSH in 20–59yo. Rates were 2.9% and 6.6%, respectively for 60–90yo.
Associations of leptin, thyroxine and thyroid stimulating hormone with cognitive performance in the 20–59yo and 60–90yo age groups: Multiple OLS and zero-inflated poisson regression models
Table 3 displays associations between the three main exposures and cognitive performance, based on multiple regression analyses. The middle tertile of leptin (vs. first tertile) was inversely related to number of errors on the symbol digits substitution test, indicating better cognition at that level (SDS-E) in 20–59yo (Table 3, Model 1). A secondary analysis examined effect modification by race. This association was stronger among NHW compared to NHB and MA (p<0.05 for associated interaction terms).
TABLE 3.
Multiple OLS and zero-inflated poisson regression analysis for predictors (thyroxine, TSH and leptin) of cognitive performance, by age group; NHANES III
| 20–59y
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SRT | SDS-L | SDS-E | SDL-TTC | SDL-TE | ||||||
| β | SEE | β | SEE | β | SEE | β | SEE | β | SEE | |
| Model 1: Leptin1 | N=1156 | N=1144 | N=1144 | N=1108 | N=1131 | |||||
| T2 vs. T1 | 5.132 | 4.703 | 0.023 | 0.630 | −0.768 | 0.255* | 0.137 | 0.291 | 0.117 | 0.476 |
| T3 vs. T1 | −8.752 | 7.693 | −0.754 | 0.686 | −0.198 | 0.424 | −0.072 | 0.431 | −0.008 | 0.720 |
| Model 2: Thyroxine1 | N=2617 | N=2593 | N=2593┼ | N=2474 | N=2526 | |||||
| T2 vs. T1 | −1.870 | 2.778 | −0.102 | 0.253 | 0.192 | 0.150 | 0.285 | 0.133* | 0.334 | 0.241 |
| T3 vs. T1 | −1.476 | 2.407 | −0.456 | 0.299 | 0.190 | 0.103 | −0.003 | 0.147 | −0.166 | 0.263 |
| Model 3: TSH1 | N=2639┼ | N=2611 | N=2611 | N=2483§ | N=2545§ | |||||
| T2 vs. T1 | 1.011 | 2.681 | 0.303 | 0.290 | 0.236 | 0.131 | −0.048 | 0.138 | 0.080 | 0.273 |
| T3 vs. T1 | 7.052 | 3.299* | 0.803 | 0.310* | 0.134 | 0.181 | −0.007 | 0.180 | 0.132 | 0.317 |
| 60–90y
|
||||||||||
| WR-CORR | WR-TRIALS | SR-CORR | MATH-INC | ORIENT-INC | ||||||
| β | SEE | β | SEE | β | SEE | β | SEE | β | SEE | |
| Model 1: Leptin1 | N=1372 | N=1362 | N=1416 | N=1468 | N=1389 | |||||
| T2 vs. T1 | −0.022 | 0.016 | 0.722 | 0.467 | −0.004 | 0.039 | 0.127 | 0.136 | −0.001 | 0.027 |
| T3 vs. T1 | −0.026 | 0.021 | 0.902 | 0.943 | −0.014 | 0.051 | −0.060 | 0.147 | −0.029 | 0.039 |
| Model 2: Thyroxine1 | N=4077 | N=5186 | N=5270┼ | N=5317§ | N=5080§ | |||||
| T2 vs. T1 | 0.007 | 0.006 | 0.113 | 0.315 | 0.113 | 0.070 | −0.220 | 0.101* | −0.004 | 0.013 |
| T3 vs. T1 | −0.011 | 0.010 | 0.040 | 0.346 | 0.142 | 0.070* | −0.247 | 0.110* | 0.001 | 0.014 |
| Model 3: TSH1 | N=4236 | N=5328 | N=5437┼ | N=5499┼;§ | N=5232 | |||||
| T2 vs. T1 | 0.005 | 0.009 | 0.220 | 0.438 | 0.219 | 0.119 | −0.312 | 0.129* | −0.030 | 0.014* |
| T3 vs. T1 | 0.015 | 0.006* | −0.031 | 0.405 | 0.291 | 0.120* | −0.265 | 0.091* | −0.019 | 0.009 |
P<0.05 for null hypothesis that β=0;
P<0.10 for null hypothesis that sex×exposure (leptin, thyroxine, TSH) interaction term γ=0 in model with sex among main effects;
P<0.10 for null hypothesis that race×exposure (leptin, thyroxine, TSH) interaction term γ=0 in model with race among main effects.
Abbreviations: MATH-INC=Math test-Incorrect; NH=Non-Hispanic; NHANES=National Health and Nutrition Examination Surveys; OLS=Ordinary Least Square; ORIENT-INC=Orientation to time, incorrect items; SDS-L=Symbol Digits Substitution tests-Latencies; SDS-E=Symbol Digits Substitution tests-Errors; Serial Digits Learning-Trials to criterion; SDL-TE=Serial Digits Learning-Total Errors; SE=Standard error; SR-CORR=Story recall-correct; SRT=Simple reaction time; WR-CORR=Word Recall-Correct; WR-TRIALS=Word Recall-Number of Trials.
All three predictors (leptin, thyroxine and TSH) were first Loge transformed and then converted to tertiles. Models were adjusted for age (continuous), sex, race, marital status (married vs. not); education (<High School; High School; >High School), poverty income ratio (0–100%; >100–200%; >200%), language of interview (English vs. Spanish), cigarette smoking status (never, former, current), self-rated health (excellent, very good, good, fair, poor),1995-healthy eating index (quintiles), physical activity (more active, about the same, less active), body mass index and a co-morbidity index. Models for the 20–59y age group were multiple OLS regression models, while those for the 60–90y age group were poisson or zero-inflated poisson regression models.
The more elevated thyroxine level was (Table 3, Model 2), the more the worse the score was on serial digits test, trials to completion (SDL-TTC) in 20–59yo, when comparing the second to the first tertile. However, this association became only borderline significant when restricting thyroxine and TSH levels to the reference range (p<0.10). Conversely, thyroxine was associated with better performance on the Math test (lower MATH-INC) and the story recall test (higher SR-CORR) in 60–90yo (Table 3, Model 2), findings that were not altered by restricting the sample to participants within the reference ranges of thyroxine and TSH (data not shown).
TSH was associated with a number of cognitive performance scores for both age groups. In 20–59yo, a higher TSH was linked to poorer performance on the simple reaction time and symbol digits substitution test-latencies (higher SRT and SDS-L), though the association with SRT became non-significant when participants outside the references ranges of thyroxine and TSH were excluded (data not shown). In contrast, increased serum level of TSH for 60–90 yo was associated with improved performance on Word recall-correct, story recall-correct, and on the Math and orientation tests. In two tests (SR-CORR and MATH-INC), the association was significantly stronger among men (p<0.05 for TSH×sex interaction term). However, only the association between TSH and SR-CORR (third vs. first tertile) and between TSH and MATH-INC (second vs. first tertile) remained statistically significant when participants outside the reference ranges of thyroxine and TSH were excluded (data not shown).
Interactions between leptin, thyroxine and TSH in their association with cognitive performance in the 20–59yo and 60–90yo age groups: Multiple OLS and zero-inflated poisson regression models
In Table 4, we tested interaction between exposures (two at a time) in affecting cognitive performance. In model 1 (with thyroxine, TSH and thyroxine×TSH), a significant antagonistic interaction (i.e. sign of the interaction term was opposite to that of the main effects) was found in both age groups, for the following cognitive performance tasks: SDS-L, SDL-TE, SR-CORR, and MATH-INC (P<0.05 for thyroxine×TSH interaction term). In model 2, an antagonistic interaction of thyroxine and leptin was observed for WR-CORR, whereby a potentially beneficial effect of thyroxine on that cognitive score was stronger at the lowest tertile of leptin (p<0.05 for leptin×thyroxine interaction term that had a positive sign in contrast to main effects of thyroxine and leptin, which had a negative sign).
TABLE 4.
Multiple OLS and zero-inflated poisson regression analysis for predictors (thyroxine, TSH and leptin) of cognitive performance: two-way interactions between exposure variables (tertiles), by age group; NHANES III
| 20–59y
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SRT | SDS-L | SDS-E | SDL-TTC | SDL-TE | ||||||
| β | SEE | β | SEE | β | SEE | β | SEE | β | SEE | |
| Model 1:1 | N=2591 | N=2567 | N=2567 | N=2449 | N=2501 | |||||
| Thyroxine | ||||||||||
| T2 vs. T1 | 0.440 | 2.881 | 0.296 | 0.299 | 0.097 | 0.148 | 0.325 | 0.129* | 0.566 | 0.229* |
| T3 vs. T1 | 2.577 | 3.044 | 0.303 | 0.440 | 0.072 | 0.268 | 0.089 | 0.194 | 0.338 | 0.319 |
| TSH | ||||||||||
| T2 vs. T1 | 2.905 | 2.919 | 0.721 | 0.317* | 0.161 | 0.158 | 0.008 | 0.145 | 0.358 | 0.296 |
| T3 vs. T1 | 10.244 | 4.300* | 1.626 | 0.511* | −0.036 | 0.314 | 0.087 | 0.237 | 0.641 | 0.399 |
| Thyroxine×TSH | −2.266 | 1.738 | −0.430 | 0.213* | 0.087 | 0.135 | −0.047 | 0.093 | −0.289 | 0.1141* |
| Model 2:1 | N=1154 | N=1142 | N=1142 | N=1107 | N=1129 | |||||
| Leptin | ||||||||||
| T2 vs. T1 | 7.650 | 6.315 | −0.629 | 0.736 | −0.790 | 0.289* | 0.051 | 0.324 | 0.036 | 0.572 |
| T3 vs. T1 | −6.759 | 7.630 | −1.177 | 0.782 | −0.221 | 0.380 | −0.127 | 0.466 | −0.010 | 0.840 |
| Thyroxine | ||||||||||
| T2 vs. T1 | −3.897 | 5.931 | −0.804 | 0.642 | 0.180 | 0.357 | −0.031 | 0.217 | 0.452 | 0.401 |
| T3 vs. T1 | 0.138 | 4.885 | −1.359 | 0.476* | −0.023 | 0.197 | −0.229 | 0.263 | −0.728 | 0.543 |
| Thyroxine×Leptin | −0.510 | 0.920 | 0.113 | 0.086 | 0.005 | 0.043 | 0.015 | 0.037 | 0.008 | 0.069 |
| Model 3:1 | N=1143 | N=1131 | N=1131 | N=1098 | N=1118 | |||||
| Leptin | ||||||||||
| T2 vs. T1 | 2.808 | 5.219 | −0.656 | 0.902 | −0.579 | 0.347 | −0.493 | 0.356 | −0.996 | 0.553 |
| T3 vs. T1 | −10.981 | 6.881 | −1.127 | 0.793 | −0.035 | 0.458 | −0.496 | 0.496 | −0.718 | 0.819 |
| TSH | ||||||||||
| T2 vs. T1 | 1.318 | 4.644 | −0.770 | 0.797 | 0.134 | 0.310 | −0.529 | 0.249* | 0.894 | 0.431* |
| T3 vs. T1 | 9.475 | 6.115 | −0.242 | 0.824 | 0.043 | 0.368 | −0.560 | 0.239* | 0.504 | 0.494 |
| TSH×Leptin | 0.332 | 0.921 | 0.156 | 0.124 | −0.007 | 0.052 | 0.143 | 0.043* | 0.248 | 0.073* |
| 60–90y
|
||||||||||
| WR-CORR | WR-TRIALS | SR-CORR | MATH-INC | ORIENT-INC | ||||||
| β | SEE | β | SEE | β | SEE | β | SEE | β | SEE | |
| Model 1:1 | N=4005 | N=5115 | N=5196 | N=5244 | N=5020 | |||||
| Thyroxine | ||||||||||
| T2 vs. T1 | −0.011 | 0.011 | 0.062 | 0.542 | 0.422 | 0.196* | −0.536 | 0.115* | −0.016 | 0.016 |
| T3 vs. T1 | −0.007 | 0.019 | −0.121 | 0.695 | 0.643 | 0.279* | −0.842 | 0.152* | −0.023 | 0.023 |
| TSH | ||||||||||
| T2 vs. T1 | 0.007 | 0.009 | 0.243 | 0.471 | 0.389 | 0.195~ | −0.459 | 0.140* | −0.036 | 0.017* |
| T3 vs. T1 | 0.020 | 0.012 | −0.147 | 0.559 | 0.655 | 0.279* | −0.591 | 0.126* | −0.035 | 0.016* |
| Thyroxine×TSH | −0.001 | 0.007 | 0.040 | 0.232 | −0.198 | 0.086* | +0.237 | 0.052* | +0.011 | 0.010 |
| Model 2:1 | N=1356 | N=1346 | N=1400 | N=1450 | N=1374 | |||||
| Leptin | ||||||||||
| T2 vs. T1 | 0.010 | 0.023 | −0.064 | 1.005 | 0.002 | 0.045 | 0.067 | 0.162 | −0.008 | 0.032 |
| T3 vs. T1 | 0.004 | 0.025 | −0.316 | 1.064 | 0.005 | 0.068 | −0.078 | 0.169 | −0.020 | 0.038 |
| Thyroxine | ||||||||||
| T2 vs. T1 | 0.041 | 0.023 | −0.062 | 1.437 | −0.011 | 0.052 | −0.083 | 0.221 | −0.010 | 0.036 |
| T3 vs. T1 | 0.028 | 0.018 | 0.297 | 0.774 | −0.042 | 0.071 | −0.095 | 0.143 | −0.022 | 0.029 |
| Thyroxine×Leptin | −0.008 | 0.003* | 0.148 | 0.170 | 0.002 | 0.011 | 0.019 | 0.026 | 0.002 | 0.006 |
| Model 3:1 | N=1348 | N=1338 | N=1390 | N=1442 | N=1364 | |||||
| Leptin | ||||||||||
| T2 vs. T1 | −0.009 | 0.034 | 6.213 | 2.886* | −0.001 | 0.059 | 0.458 | 0.168* | −0.033 | 0.038 |
| T3 vs. T1 | −0.007 | 0.031 | 5.258 | 2.008* | −0.004 | 0.063 | 0.066 | 0.665 | −0.043 | 0.037 |
| TSH | ||||||||||
| T2 vs. T1 | 0.017 | 0.029 | 6.792 | 2.461* | 0.002 | 0.059 | 0.324 | 0.185~ | −0.037 | 0.045 |
| T3 vs. T1 | 0.021 | 0.024 | 4.607 | 1.689* | 0.047 | 0.045 | 0.261 | 0.170 | −0.028 | 0.037 |
| TSH×Leptin | −0.003 | 0.004 | −0.679 | 0.348~ | −0.001 | 0.009 | −0.057 | 0.038 | 0.003 | 0.006 |
P<0.10
P<0.05 for null hypothesis that β=0.
Abbreviations: MATH-INC=Math test-Incorrect; NH=Non-Hispanic; NHANES=National Health and Nutrition Examination Surveys; OLS=Ordinary Least Square; ORIENT-INC=Orientation to time, incorrect items; SDS-L=Symbol Digits Substitution tests-Latencies; SDS-E=Symbol Digits Substitution tests-Errors; Serial Digits Learning-Trials to criterion; SDL-TE=Serial Digits Learning-Total Errors; SE=Standard error; SR-CORR=Story recall-correct; SRT=Simple reaction time; WR-CORR=Word Recall-Correct; WR-TRIALS=Word Recall-Number of Trials.
All three predictors (leptin, thyroxine and TSH) were first Loge transformed and then converted to tertiles. Models were adjusted for age (continuous), sex, race, marital status (married vs. not); education (<High School; High School; >High School), poverty income ratio (0–100%; >100–200%; >200%), language of interview (English vs. Spanish), cigarette smoking status (never, former, current), self-rated health (excellent, very good, good, fair, poor), 1995-healthy eating index (quintiles), phyiscal activity (more active, about the same, less active), body mass index and a co-morbidity index. Models for the 20–59y age group were multiple OLS regression models, while those for the 60–90y age group were poisson or zero-inflated poisson regression models.
Finally, there were also antagonistic interactions between TSH and leptin (model 3) in their associations with SDL-TE and SDL-TTC. In particular, higher levels of TSH were associated with better cognition, particularly at lower levels of leptin. Most significant findings were unaltered by excluding participants outside the reference ranges of thyroxine and TSH. (data not shown).
DISCUSSION
This cross-sectional study of a nationally representative sample of US adults examined the associations of leptin, thyroxine and TSH with cognitive test performance in 20–59yo and 60–90yo. We also examined interactions between the three exposures in their associations with cognitive performance. Among those 20–59yo, the middle tertile of leptin (vs. first tertile) was inversely related to the number of errors on the symbol digits substitution test. Increased thyroxine level was associated with a poorer performance on the serial digits test in 20–59yo, but a better performance on the Math and story recall tests in 60–90yo. TSH was associated with poor performance on various tests in 20–59yo, but better performance in 60–90yo. Significant antagonistic interactions were found in both age groups between thyroxine, TSH and leptin for a number of tests, including between leptin and thyroxine in 60–90yo in their association with word recall-correct score as well as leptin and TSH in 20–59yo in their association with serial digits learning test scores.
Overall, a limited number of cross-sectional, cohort and experimental studies have examined the effect of thyroid function on various cognitive outcomes. Out of ten cross-sectional studies (Almeida, et al., 2007, Cardenas-Ibarra, et al., 2008, Ceresini, et al., 2009, Kramer, et al., 2009, Prinz, et al., 1999, Samuels, et al., 2007b, Stern, et al., 2004, Stuerenburg, et al., 2006, Wahlin, et al., 1998, Wu, et al., 2006), six suggested that either hypothyroidism or hyperthyroidism may be linked to adverse cognitive outcomes, two had mixed results (Wahlin, et al., 1998, Wu, et al., 2006) and two had no significant results (Almeida, et al., 2007, Kramer, et al., 2009). Out of four cohort studies (de Jong, et al., 2009, Gussekloo, et al., 2004, Hogervorst, et al., 2008, Volpato, et al., 2002), three suggested positive (de Jong, et al., 2009, Hogervorst, et al., 2008, Volpato, et al., 2002), and one suggested negative findings (Gussekloo, et al., 2004). In one of the positive studies (de Jong, et al., 2009), 1 standard deviation higher serum free thyroxine was associated on average with 20–30% increased risk of dementia and AD among Japanese-American men aged 71–93y (n=665). Another large cohort study (n=599) conducted in the Netherlands, also among a group of older adults, did not find an association between thyroid status at baseline and cognitive function (Gussekloo, et al., 2004). Out of seven experimental studies (Bono, et al., 2004, Burmeister, et al., 2001, Correia, et al., 2009, Miller, et al., 2006, Monzani, et al., 1993, Osterweil, et al., 1992, Samuels, et al., 2007b), four had positive findings (Bono, et al., 2004, Correia, et al., 2009, Monzani, et al., 1993, Samuels, et al., 2007b) and three had mixed findings (Burmeister, et al., 2001, Miller, et al., 2006, Osterweil, et al., 1992). For instance, in an intervention study on 21 hypothyroids and 17 sub-clinical hypothyroid patients, neuropsychological testing was administered at baseline and then 3 and 6 months after T4 replacement and compared to normal participants. After T4 replacement, verbal memory normalized in both overt and sub-clinical hypothyroid groups. Spatial memory normalized in the sub-clinical group but remained impaired in the overtly hypothyroid group. Associative memory deficits persisted in the overt hypothyroid group (Correia, et al., 2009).
Our findings are of great importance as they point to different directions of associations between thyroid hormones and cognition in younger versus older adults. In particular, among younger and middle-aged adults, thyroxine (T4) and TSH were shown to have a deleterious effect on cognition in the domains of learning, reaction time and psychomotor speed. Few studies have investigated the same domains and population, but some similar findings have been observed in earlier studies. For instance, an investigation of adult hypothyroid patients demonstrated deficits in the areas of verbal learning and psychomotor functioning, that was partially ameliorated with thyroid treatment (Osterweil, et al., 1992). In contrast, among older adults, thyroxine and TSH were shown to be related to an improved cognitive performance in domains of verbal memory, attention/calculation and orientation to time. Similar findings were observed in a number of previous cross-sectional (Ceresini, et al., 2009, Kramer, et al., 2009) and longitudinal studies (Miller, et al., 2006, Samuels, et al., 2007a, Volpato, et al., 2002). For instance, older adults with subclinical hypothyroidism had poorer MMSE scores (Kramer, et al., 2009) than euthyroid adults, and MMSE scores for adults who underwent 20 years of thyroid treatment were no different than euthyroid adults (Miller, et al., 2006). Longitudinally, hypothyroid patients who underwent 3 months of thyroxine treatment increased their performance on verbal memory (Miller, et al., 2006), while older women with greater 3-year thyroxine declines (lowest thyroxine tertile) had greater decreases in MMSE score (Volpato, et al., 2002) when compared with women in the highest thyroxine tertile.
We identified one cross-sectional (Gunstad, et al., 2008) and two cohort studies (Holden, et al., 2009, Lieb, et al., 2009) that examined the effect of leptin levels on cognition, dementia or Alzheimer’s disease. In the cohort study (Health ABC, n=2871, age: 70–79y), participants in the high leptin group were at 34% lower risk for clinically significant cognitive decline over 4 years (≥5-point drop on the 3MS) compared to the lowest group; (OR=0.66; (95% CI: 0.48–0.91), independent of co-morbidities and body fat(Holden, et al., 2009). In another more recent prospective study of 785 persons without dementia (Framingham study, mean age (SD), 79y (5) 62% female), higher leptin was associated with lower risk of incident dementia and AD in multivariable models (hazard ratio per 1-SD increment in log leptin was 0.68 (95% confidence interval, 0.54–0.87) for all-cause dementia and 0.60 (95% confidence interval, 0.46–0.79) for AD(Lieb, et al., 2009). In contrast, in the cross-sectional study (n=35; mean age: 74y), serum leptin was inversely related to speeded executive function in older adults who had no significant neurological or psychiatric conditions(Gunstad, et al., 2008).
Various biological mechanisms can explain the potential associations between thyroxine, TSH and cognition. First, the concentrations of both T4 and its more potent metabolite T3 are preserved at narrow ranges within the brain, independently of fluctuations of their respective values in the bloodstream (Dratman, et al., 1983), suggesting that even small changes within the brain may have major impacts on behavior(Loosen, 1992). Second, T3 in brain is mostly derived from circulating T4 through local enzymatic deiodination (5′D-II diodinase), rather than through active transport of circulating T3 into brain tissue(Crantz, et al., 1982). Finally, thyroid hormones in a number of animal studies were shown to reduce the expression of the β-amyloid precursor protein gene(Belandia, et al., 1998).
However, other external factors may influence the level of thyroxine and the association between thyroxine and TSH in serum. In fact, the major part of T4 (>99%) does not circulate freely but rather binds to thyroxine-binding globulin, thyroxin-binding prealbumin, and albumin, and thus the active form of T4 is accounted only by 1% of total T4. Serum level of thyroxine-binding proteins is greatly determined by other factors in older persons including estrogens, corticosteroid use and liver or renal disease (Surks, et al., 1990). Thus, our findings may be confounded by those external factors, especially in the older age group. Moreover, among healthy participants, the association between thyroxine and TSH was shown to be inverse log-linear. In our study this was the case, with a weak inverse but significant association (r~0.20). This weak association suggests that other factors are at play, including the effect of several neurotransmitters on thyroid hormones (somatostatin, cortisol, and cytokines) (Robbins, 1996) and the reduced response of TSH to thyroid releasing hormone with aging among others (Mariotti, et al., 1995).
Similarly, a number of biological mechanisms were suggested to explain leptin’s association with cognition. First, leptin may play a role in hippocampal synaptic plasticity that is related to learning and memory and is implicated in leptin induced long-term potentiation (LTP)(Harvey, et al., 2006, Shanley, et al., 2001). Second, it regulates neuron excitability by modulating cognitive ability through AMPK signaling pathway(Harvey, et al., 2006). Third, leptin may act as an anti-apoptotic agent under stress condition and have neuro-protective function (Doherty, et al., 2008, Guo, et al., 2008, Weng, et al., 2007, Zhang, et al., 2007). Fourth, leptin was shown to promote Apolipoprotein-E dependent beta-amyloid re-uptake into the cell, thus reducing its deposition in the extracellular space (Fewlass, et al., 2004). Finally, leptin and insulin act synergistically to reduce the amount of hyperphosphorylation of tau, the main component of the neurofibrillary tangle which constitutes a major hallmark for AD (Greco, et al., 2008). Importantly, treatment of transgenic mice (AD model) with leptin was shown to trigger improvements in memory tasks(Tezapsidis, et al., 2009).
The antagonistic interaction between thyroxine and TSH may be explained by the fact that mild hypothyroidism, with a prevalence of 5–10% in the general population, is a condition in which T3 and T4 are in the normal range while TSH is high. This condition was linked to a number of signs and symptoms including fatigue, poor memory and a slow thinking process, particularly among older women (Canaris, et al., 2000, Evered, et al., 1973, McDermott and Ridgway, 2001). Similarly, the antagonistic interaction between leptin and thyroxine may be due to the function of megalin (also called low-density lipoprotein receptor-related protein-2 [LRP2]), which is an endocytic receptor expressed in a number of epithelial cells including those of the choroid plexus (i.e. blood-brain barrier) and belongs to the low-density lipoprotein (LDL) receptor family. Megalin mediates the transport of both leptin and thyroxine through the blood-brain barrier (Dietrich, et al., 2008, Lisi, et al., 2005), and thus those two hormones may be competing for the same receptor to enter the brain.
Our study has many strengths, including the use of a large nationally representative sample, the inclusion of a wide age range of adults (20–59y and 60–90y) and tests that span a variety of cognitive domains. However, our study is limited because it is cross-sectional so no causal link can be ascertained between the exposures and outcomes. Thus, prospective cohort studies, and ultimately a randomized controlled trial, are needed to better examine the effects of baseline serum leptin, thyroxine and TSH on decline in various domains of cognition and for different age groups. Another limitation is that the type of cognitive tests differed between the two age groups despite spanning a number of domains in both, which did not allow to examine effect modification of the main associations of interest by age per se. In addition, the lack of data on free thyroxine (T3 or T4), or thyroxine binding globulin is a major limitation and does not allow for comparison with many of the previous studies which have used those measures instead of total thyroxine level. This has also precluded forming clinically relevant categories that were based on free thyroxine and TSH for hypo and hyperthyroidism as was done previously by others (Gussekloo, et al., 2004). Finally, residual confounding cannot be ruled out even though major potential confounders were adjusted for in our analyses.
In conclusion, our study findings suggest that there are significant associations of serum leptin, thyroxine and TSH with cognitive function among adults, though some of those associations (particulary those of thyroid function) differ markedly between the two age groups of interest. It is important to conduct prospective cohort studies to examine age-related cognitive decline in relation to exposures of interest that would provide further insight into potential interventions that would assess interactive effects of various hormonal replacement regimens.
Supplementary Material
Acknowledgments
The authors would like to thank Drs. Lori L. Beason-Held and Alyssa Gamaldo for their internal review of this manuscript. This research was supported entirely by the Intramural Research Program of the NIH, National Institute on Aging.
Footnotes
The authors declare no conflict of interest.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
- Almeida C, Vaisman M, Costa AJ, Reis FA, Reuters V, Teixeira P, Ferreira M, Teixeira LB, Araujo GR, Brasil MA. Are neuropsychological changes relevant in subclinical hypothyroidism? Arq Bras Endocrinol Metabol. 2007;51(4):606–11. doi: 10.1590/s0004-27302007000400016. S0004-27302007000400016 [pii] [DOI] [PubMed] [Google Scholar]
- Anderson GW. Thyroid hormones and the brain. Front Neuroendocrinol. 2001;22(1):1–17. doi: 10.1006/frne.2000.0208. S0091-3022(00)90208-5 [pii] [DOI] [PubMed] [Google Scholar]
- Bauer M, Whybrow PC. Thyroid hormone, neural tissue and mood modulation. World J Biol Psychiatry. 2001;2(2):59–69. doi: 10.3109/15622970109027495. [DOI] [PubMed] [Google Scholar]
- Belandia B, Latasa MJ, Villa A, Pascual A. Thyroid hormone negatively regulates the transcriptional activity of the beta-amyloid precursor protein gene. J Biol Chem. 1998;273(46):30366–71. doi: 10.1074/jbc.273.46.30366. [DOI] [PubMed] [Google Scholar]
- Beydoun MA, Beydoun HA, Wang Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes Rev. 2008;9(3):204–18. doi: 10.1111/j.1467-789X.2008.00473.x. OBR473 [pii] [DOI] [PMC free article] [PubMed] [Google Scholar]
- Biondi B. Thyroid and obesity: an intriguing relationship. J Clin Endocrinol Metab. 2010;95(8):3614–7. doi: 10.1210/jc.2010-1245. 95/8/3614 [pii] [DOI] [PubMed] [Google Scholar]
- Bono G, Fancellu R, Blandini F, Santoro G, Mauri M. Cognitive and affective status in mild hypothyroidism and interactions with L-thyroxine treatment. Acta Neurol Scand. 2004;110(1):59–66. doi: 10.1111/j.1600-0404.2004.00262.x. ANE262 [pii] [DOI] [PubMed] [Google Scholar]
- Burmeister LA, Ganguli M, Dodge HH, Toczek T, DeKosky ST, Nebes RD. Hypothyroidism and cognition: preliminary evidence for a specific defect in memory. Thyroid. 2001;11(12):1177–85. doi: 10.1089/10507250152741037. [DOI] [PubMed] [Google Scholar]
- Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4):526–34. doi: 10.1001/archinte.160.4.526. [DOI] [PubMed] [Google Scholar]
- Cardenas-Ibarra L, Solano-Velazquez JA, Salinas-Martinez R, Aspera-Ledezma TD, Sifuentes-Martinez Mdel R, Villarreal-Perez JZ. Cross-sectional observations of thyroid function in geriatric Mexican outpatients with and without dementia. Arch Gerontol Geriatr. 2008;46(2):173–80. doi: 10.1016/j.archger.2007.03.009. S0167-4943(07)00105-7 [pii] [DOI] [PubMed] [Google Scholar]
- Center for Disease Control and Prevention (CDC) The Third National Health and Nutrition Examination Survey (NHANES III 1988–94) Reference Manuals and Reports (CD-ROM) Bethesda, MD: Centers for Disease Control and Prevention; 1996. [Google Scholar]
- Ceresini G, Lauretani F, Maggio M, Ceda GP, Morganti S, Usberti E, Chezzi C, Valcavi R, Bandinelli S, Guralnik JM, Cappola AR, Valenti G, Ferrucci L. Thyroid function abnormalities and cognitive impairment in elderly people: results of the Invecchiare in Chianti study. J Am Geriatr Soc. 2009;57(1):89–93. doi: 10.1111/j.1532-5415.2008.02080.x. JGS2080 [pii] [DOI] [PMC free article] [PubMed] [Google Scholar]
- Correia N, Mullally S, Cooke G, Tun TK, Phelan N, Feeney J, Fitzgibbon M, Boran G, O’Mara S, Gibney J. Evidence for a specific defect in hippocampal memory in overt and subclinical hypothyroidism. J Clin Endocrinol Metab. 2009;94(10):3789–97. doi: 10.1210/jc.2008-2702. jc.2008-2702 [pii] [DOI] [PubMed] [Google Scholar]
- Crantz FR, Silva JE, Larsen PR. An analysis of the sources and quantity of 3,5,3′-triiodothyronine specifically bound to nuclear receptors in rat cerebral cortex and cerebellum. Endocrinology. 1982;110(2):367–75. doi: 10.1210/endo-110-2-367. [DOI] [PubMed] [Google Scholar]
- de Jong FJ, Masaki K, Chen H, Remaley AT, Breteler MM, Petrovitch H, White LR, Launer LJ. Thyroid function, the risk of dementia and neuropathologic changes: the Honolulu-Asia aging study. Neurobiol Aging. 2009;30(4):600–6. doi: 10.1016/j.neurobiolaging.2007.07.019. S0197-4580(07)00301-6 [pii] [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dietrich MO, Spuch C, Antequera D, Rodal I, de Yebenes JG, Molina JA, Bermejo F, Carro E. Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiol Aging. 2008;29(6):902–12. doi: 10.1016/j.neurobiolaging.2007.01.008. S0197-4580(07)00009-7 [pii] [DOI] [PubMed] [Google Scholar]
- Doherty GH, Oldreive C, Harvey J. Neuroprotective actions of leptin on central and peripheral neurons in vitro. Neuroscience. 2008;154(4):1297–307. doi: 10.1016/j.neuroscience.2008.04.052. [DOI] [PubMed] [Google Scholar]
- Dratman MB, Crutchfield FL, Gordon JT, Jennings AS. Iodothyronine homeostasis in rat brain during hypo- and hyperthyroidism. Am J Physiol. 1983;245(2):E185–93. doi: 10.1152/ajpendo.1983.245.2.E185. [DOI] [PubMed] [Google Scholar]
- Dugbartey AT. Neurocognitive aspects of hypothyroidism. Arch Intern Med. 1998;158(13):1413–8. doi: 10.1001/archinte.158.13.1413. [DOI] [PubMed] [Google Scholar]
- Evered DC, Ormston BJ, Smith PA, Hall R, Bird T. Grades of hypothyroidism. Br Med J. 1973;1(5854):657–62. doi: 10.1136/bmj.1.5854.657. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Farooqi IS, Bullmore E, Keogh J, Gillard J, O’Rahilly S, Fletcher PC. Leptin regulates striatal regions and human eating behavior. Science. 2007;317(5843):1355. doi: 10.1126/science.1144599. 1144599 [pii] [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fewlass DC, Noboa K, Pi-Sunyer FX, Johnston JM, Yan SD, Tezapsidis N. Obesity-related leptin regulates Alzheimer’s Abeta. FASEB J. 2004;18(15):1870–8. doi: 10.1096/fj.04-2572com. 18/15/1870 [pii] [DOI] [PubMed] [Google Scholar]
- Folstein MF, Folstein SE, McHugh PR. “Mini-mental state” a practical Method for grading the cognitive state of patients for the clinician. J Psychiat Res. 1975;12:189–98. doi: 10.1016/0022-3956(75)90026-6. [DOI] [PubMed] [Google Scholar]
- Greco SJ, Sarkar S, Johnston JM, Zhu X, Su B, Casadesus G, Ashford JW, Smith MA, Tezapsidis N. Leptin reduces Alzheimer’s disease-related tau phosphorylation in neuronal cells. Biochem Biophys Res Commun. 2008;376(3):536–41. doi: 10.1016/j.bbrc.2008.09.026. S0006-291X(08)01768-3 [pii] [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gunstad J, Spitznagel MB, Keary TA, Glickman E, Alexander T, Karrer J, Stanek K, Reese L, Juvancic-Heltzel J. Serum leptin levels are associated with cognitive function in older adults. Brain Res. 2008;1230:233–6. doi: 10.1016/j.brainres.2008.07.045. S0006-8993(08)01745-9 [pii] [DOI] [PubMed] [Google Scholar]
- Gunter EW, Lewis BG, Koncikowski SM. Laboratory Procedures Used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994. US DHHS, Public Health Service, Centers for Disease Control and Prevention, National Center for Environmental Health and National Center for Health Statistics; Atlanta, GA and Hyattsville, MD: 2010. http://www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom/nchs/manuals/labman.pdf. [Google Scholar]
- Guo Z, Jiang H, Xu X, Duan W, Mattson MP. Leptin-mediated cell survival signaling in hippocampal neurons mediated by JAK STAT3 and mitochondrial stabilization. J Biol Chem. 2008;283(3):1754–63. doi: 10.1074/jbc.M703753200. [DOI] [PubMed] [Google Scholar]
- Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA. 2004;292(21):2591–9. doi: 10.1001/jama.292.21.2591. 292/21/2591 [pii] [DOI] [PubMed] [Google Scholar]
- Harvey J, Shanley LJ, O’Malley D, Irving AJ. Leptin: a potential cognitive enhancer? Biochem Soc Trans. 2005;33(Pt 5):1029–32. doi: 10.1042/BST20051029. [DOI] [PubMed] [Google Scholar]
- Harvey J, Solovyova N, Irving A. Leptin and its role in hippocampal synaptic plasticity. Prog Lipid Res. 2006;45(5):369–78. doi: 10.1016/j.plipres.2006.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hendrick V, Altshuler L, Whybrow P. Psychoneuroendocrinology of mood disorders. The hypothalamic-pituitary-thyroid axis. Psychiatr Clin North Am. 1998;21(2):277–92. doi: 10.1016/s0193-953x(05)70005-8. [DOI] [PubMed] [Google Scholar]
- Hogervorst E, Huppert F, Matthews FE, Brayne C. Thyroid function and cognitive decline in the MRC Cognitive Function and Ageing Study. Psychoneuroendocrinology. 2008;33(7):1013–22. doi: 10.1016/j.psyneuen.2008.05.008. S0306-4530(08)00126-1 [pii] [DOI] [PubMed] [Google Scholar]
- Holden KF, Lindquist K, Tylavsky FA, Rosano C, Harris TB, Yaffe K. Serum leptin level and cognition in the elderly: Findings from the Health ABC Study. Neurobiol Aging. 2009;30(9):1483–9. doi: 10.1016/j.neurobiolaging.2007.11.024. S0197-4580(07)00454-X [pii] [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jacob RJ, Dziura J, Medwick MB, Leone P, Caprio S, During M, Shulman GI, Sherwin RS. The effect of leptin is enhanced by microinjection into the ventromedial hypothalamus. Diabetes. 1997;46(1):150–2. doi: 10.2337/diab.46.1.150. [DOI] [PubMed] [Google Scholar]
- Kramer CK, von Muhlen D, Kritz-Silverstein D, Barrett-Connor E. Treated hypothyroidism, cognitive function, and depressed mood in old age: the Rancho Bernardo Study. Eur J Endocrinol. 2009;161(6):917–21. doi: 10.1530/EJE-09-0606. EJE-09-0606 [pii] [DOI] [PubMed] [Google Scholar]
- Lieb W, Beiser AS, Vasan RS, Tan ZS, Au R, Harris TB, Roubenoff R, Auerbach S, DeCarli C, Wolf PA, Seshadri S. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA. 2009;302(23):2565–72. doi: 10.1001/jama.2009.1836. 302/23/2565 [pii] [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lisi S, Segnani C, Mattii L, Botta R, Marcocci C, Dolfi A, McCluskey RT, Pinchera A, Bernardini N, Marino M. Thyroid dysfunction in megalin deficient mice. Mol Cell Endocrinol. 2005;236(1–2):43–7. doi: 10.1016/j.mce.2005.03.009. S0303-7207(05)00125-5 [pii] [DOI] [PubMed] [Google Scholar]
- Loosen PT. Effects of thyroid hormones on central nervous system in aging. Psychoneuroendocrinology. 1992;17(4):355–74. doi: 10.1016/0306-4530(92)90041-5. [DOI] [PubMed] [Google Scholar]
- Mafrica F, Fodale V. Thyroid function, Alzheimer’s disease and postoperative cognitive dysfunction: a tale of dangerous liaisons? J Alzheimers Dis. 2008;14(1):95–105. doi: 10.3233/jad-2008-14109. [DOI] [PubMed] [Google Scholar]
- Mariotti S, Franceschi C, Cossarizza A, Pinchera A. The aging thyroid. Endocr Rev. 1995;16(6):686–715. doi: 10.1210/edrv-16-6-686. [DOI] [PubMed] [Google Scholar]
- McCullough ML, Feskanich D, Rimm EB, Giovannucci EL, Ascherio A, Variyam JN, Spiegelman D, Stampfer MJ, Willett WC. Adherence to the Dietary Guidelines for Americans and risk of major chronic disease in men. Am J Clin Nutr. 2000;72(5):1223–31. doi: 10.1093/ajcn/72.5.1223. [DOI] [PubMed] [Google Scholar]
- McDermott MT, Ridgway EC. Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Metab. 2001;86(10):4585–90. doi: 10.1210/jcem.86.10.7959. [DOI] [PubMed] [Google Scholar]
- Miller KJ, Parsons TD, Whybrow PC, van Herle K, Rasgon N, van Herle A, Martinez D, Silverman DH, Bauer M. Memory improvement with treatment of hypothyroidism. Int J Neurosci. 2006;116(8):895–906. doi: 10.1080/00207450600550154. N7116813534X7616 [pii] [DOI] [PubMed] [Google Scholar]
- Monzani F, Del Guerra P, Caraccio N, Pruneti CA, Pucci E, Luisi M, Baschieri L. Subclinical hypothyroidism: neurobehavioral features and beneficial effect of L-thyroxine treatment. Clin Investig. 1993;71(5):367–71. doi: 10.1007/BF00186625. [DOI] [PubMed] [Google Scholar]
- Morrison CD. Leptin signaling in brain: A link between nutrition and cognition? Biochim Biophys Acta. 2009;5:401–8. doi: 10.1016/j.bbadis.2008.12.004. 1792. S0925-4439(08)00251-2 [pii] [DOI] [PMC free article] [PubMed] [Google Scholar]
- Osterweil D, Syndulko K, Cohen SN, Pettler-Jennings PD, Hershman JM, Cummings JL, Tourtellotte WW, Solomon DH. Cognitive function in non-demented older adults with hypothyroidism. J Am Geriatr Soc. 1992;40(4):325–35. doi: 10.1111/j.1532-5415.1992.tb02130.x. [DOI] [PubMed] [Google Scholar]
- Paz-Filho GJ, Babikian T, Asarnow R, Delibasi T, Esposito K, Erol HK, Wong ML, Licinio J. Leptin replacement improves cognitive development. PLoS One. 2008;3(8):e3098. doi: 10.1371/journal.pone.0003098. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Prinz PN, Scanlan JM, Vitaliano PP, Moe KE, Borson S, Toivola B, Merriam GR, Larsen LH, Reed HL. Thyroid hormones: positive relationships with cognition in healthy, euthyroid older men. J Gerontol A Biol Sci Med Sci. 1999;54(3):M111–6. doi: 10.1093/gerona/54.3.m111. [DOI] [PubMed] [Google Scholar]
- Robbins J. Thyroid hormone transport proteins and the physiology of hormone binding. In: Braverman LE, Utiger RD, editors. The thyroid: a fundamental and clinical text. Lippincott-Raven; Philadelphia: 1996. pp. 96–111. [Google Scholar]
- Samuels MH, Schuff KG, Carlson NE, Carello P, Janowsky JS. Health status, mood, and cognition in experimentally induced subclinical hypothyroidism. J Clin Endocrinol Metab. 2007a;92(7):2545–51. doi: 10.1210/jc.2007-0011. jc.2007-0011 [pii] [DOI] [PubMed] [Google Scholar]
- Samuels MH, Schuff KG, Carlson NE, Carello P, Janowsky JS. Health status, psychological symptoms, mood, and cognition in L-thyroxine-treated hypothyroid subjects. Thyroid. 2007b;17(3):249–58. doi: 10.1089/thy.2006.0252. [DOI] [PubMed] [Google Scholar]
- Selvin S. Statistical Analysis of Epidemiologic Data. 3. Oxford University Press; 2004. [Google Scholar]
- Shanley LJ, Irving AJ, Harvey J. Leptin enhances NMDA receptor function and modulates hippocampal synaptic plasticity. J Neurosci. 2001;21(24):RC186. doi: 10.1523/JNEUROSCI.21-24-j0001.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Smith JW, Evans AT, Costall B, Smythe JW. Thyroid hormones, brain function and cognition: a brief review. Neurosci Biobehav Rev. 2002;26(1):45–60. doi: 10.1016/s0149-7634(01)00037-9. S0149763401000379 [pii] [DOI] [PubMed] [Google Scholar]
- STATA. Statistics/Data Analysis: Release 11.0. Stata Corporation; Texas: 2009. [Google Scholar]
- Stern RA, Davis JD, Rogers BL, Smith KE, Harrington CJ, Ott BR, Jackson IM, Prange AJ., Jr Preliminary study of the relationship between thyroid status and cognitive and neuropsychiatric functioning in euthyroid patients with Alzheimer dementia. Cogn Behav Neurol. 2004;17(4):219–23. 00146965-200412000-00007 [pii] [PubMed] [Google Scholar]
- Stuerenburg HJ, Arlt S, Mueller-Thomsen T. Free thyroxine, cognitive decline and depression in Alzheimer’s disease. Neuro Endocrinol Lett. 2006;27(4):535–7. NEL270406A24 [pii] [PubMed] [Google Scholar]
- Surks MI, Chopra IJ, Mariash CN, Nicoloff JT, Solomon DH. American Thyroid Association guidelines for use of laboratory tests in thyroid disorders. JAMA. 1990;263(11):1529–32. [PubMed] [Google Scholar]
- Tezapsidis N, Johnston JM, Smith MA, Ashford JW, Casadesus G, Robakis NK, Wolozin B, Perry G, Zhu X, Greco SJ, Sarkar S. Leptin: a novel therapeutic strategy for Alzheimer’s disease. J Alzheimers Dis. 2009;16(4):731–40. doi: 10.3233/JAD-2009-1021. 3375752606620632 [pii] [DOI] [PMC free article] [PubMed] [Google Scholar]
- US DHHS, P.H.S., Centers for Disease Control and Prevention, National Center for Environmental Health and National Center for Health Statistics. Documentation on leptin assay. Atlanta, GA and Hyattsville, MD: 2002. ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Datasets/NHANES/NHANESIII/12A/le-acc.pdf. [Google Scholar]
- Volpato S, Guralnik JM, Fried LP, Remaley AT, Cappola AR, Launer LJ. Serum thyroxine level and cognitive decline in euthyroid older women. Neurology. 2002;58(7):1055–61. doi: 10.1212/wnl.58.7.1055. [DOI] [PubMed] [Google Scholar]
- Wahlin A, Wahlin TB, Small BJ, Backman L. Influences of thyroid stimulating hormone on cognitive functioning in very old age. J Gerontol B Psychol Sci Soc Sci. 1998;53(4):234–9. doi: 10.1093/geronb/53b.4.p234. [DOI] [PubMed] [Google Scholar]
- Weng Z, Signore AP, Gao Y, Wang S, Zhang F, Hastings T, Yin XM, Chen J. Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling. J Biol Chem. 2007;282(47):34479–91. doi: 10.1074/jbc.M705426200. [DOI] [PubMed] [Google Scholar]
- Wu T, Flowers JW, Tudiver F, Wilson JL, Punyasavatsut N. Subclinical thyroid disorders and cognitive performance among adolescents in the United States. BMC Pediatr. 2006;6:12. doi: 10.1186/1471-2431-6-12. 1471-2431-6-12 [pii] [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhang F, Wang S, Signore AP, Chen J. Neuroprotective effects of leptin against ischemic injury induced by oxygen-glucose deprivation and transient cerebral ischemia. Stroke. 2007;38(8):2329–36. doi: 10.1161/STROKEAHA.107.482786. [DOI] [PubMed] [Google Scholar]
- Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425–32. doi: 10.1038/372425a0. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.



